Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Tuscano

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Managed Care (Langhorne, Pa.)|December 20, 2008
Multiple myeloma: epidemiology and therapeutic optionsJoseph M Tuscano
Biologics : Targets & Therapy|August 27, 2009
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritisJoseph M Tuscano, Jacob Sands
Autoimmunity Reviews|November 17, 2009
Geoepidemiology and autoimmune manifestations of lymphoproliferative disordersJacob Sands, Joseph M Tuscano
Leukemia Research|December 5, 2003
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphomaTed Wun, Hayes McKnight, Joseph M Tuscano
Frontiers in Oncology|November 3, 2023
Checkpoint inhibition in hematologic malignanciesAaron Tsumura, Daniel Levis, Joseph M Tuscano
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 23, 2013
Targeting CD22 in B-cell malignancies: current status and clinical outlookLoretta Sullivan-Chang, Robert T O'Donnell, Joseph M Tuscano
Autoimmunity Reviews|January 15, 2014
Diagnosis and classification of autoimmune hemolytic anemiaGarrett F Bass, Emily T Tuscano, Joseph M Tuscano
Autoimmunity Reviews|July 10, 2003
B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implicationsJoseph M Tuscano, Geoffrey S Harris, Thomas F Tedder
Hematology (Amsterdam, Netherlands)|December 3, 2005
B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritisJoseph M Tuscano, Shiloh Martin, Kyle Song, et al.
Oncoimmunology|December 25, 2012
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaJason Kato, Robert T O'Donnell, Mastewal Abuhay, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Managed Care (Langhorne, Pa.)|December 20, 2008
Multiple myeloma: epidemiology and therapeutic optionsJoseph M Tuscano
Biologics : Targets & Therapy|August 27, 2009
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritisJoseph M Tuscano, Jacob Sands
Autoimmunity Reviews|November 17, 2009
Geoepidemiology and autoimmune manifestations of lymphoproliferative disordersJacob Sands, Joseph M Tuscano
Leukemia Research|December 5, 2003
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphomaTed Wun, Hayes McKnight, Joseph M Tuscano
Frontiers in Oncology|November 3, 2023
Checkpoint inhibition in hematologic malignanciesAaron Tsumura, Daniel Levis, Joseph M Tuscano
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 23, 2013
Targeting CD22 in B-cell malignancies: current status and clinical outlookLoretta Sullivan-Chang, Robert T O'Donnell, Joseph M Tuscano
Autoimmunity Reviews|January 15, 2014
Diagnosis and classification of autoimmune hemolytic anemiaGarrett F Bass, Emily T Tuscano, Joseph M Tuscano
Autoimmunity Reviews|July 10, 2003
B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implicationsJoseph M Tuscano, Geoffrey S Harris, Thomas F Tedder
Hematology (Amsterdam, Netherlands)|December 3, 2005
B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritisJoseph M Tuscano, Shiloh Martin, Kyle Song, et al.
Oncoimmunology|December 25, 2012
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaJason Kato, Robert T O'Donnell, Mastewal Abuhay, et al.
Pageof 7